RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Canopy Growth Burns Cash Again in Q3

Canopy Growth Reports Third Quarter Fiscal Year 2024 Financial Results; Achieves Third Quarter of Sequential Revenue Growth across Canada Cannabis Businesses and a Record Quarter

February 9, 2024

New intranasal vaccine candidate triggers powerful mucosal defense against SARS-CoV-2

A team of scientists, led by Duke-NUS Medical School, has discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against SARS-CoV-2 viruses compared

January 10, 2024

Smaller employers weigh a big-company fix for scarce primary care: Their own clinics

With his company’s health costs soaring and his workers struggling with high blood pressure and other medical conditions, Winston Griffin, CEO of Laurel Grocery Co.,

October 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.